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Objective: To evaluate patient characteristics and practice patterns in the management of
acute asthma attack at tertiary care centers across Turkey.
Methods: A total of 294 patients (mean age: 50.4  15.1 years; females: 80.3%) diagnosed with
persistent asthma were included in this retrospective study upon their admission to the
hospital with an acute asthma attack. Patient demographics, asthma control level, asthma
attack severity and the management of the attack were evaluated.
Results: There was no influence of gender on asthma control and attack severity. In 57.5% of the
patients, asthmaattackwasmoderate.Mostpatients (78.9%)werehospitalizedwith longerduration
evident in thesevereattack.SpirometryandchestX-Raywere themost frequent tests (85.4%),while
steroids (72.0% parenteral; 29.0% oral) and short-acting beta-agonists (SABA) þ anticholinergics
(45.5%) were the main drugs of choice in the attack management. Attack severity and pre-attack
asthma control level was significantly correlated (p < 0.001). Pre-attack asthma was uncontrolled
in 42.6% of the patients with severe attack. Most of the patients were on combination ofmore than
one (two in 38.7% and 3e4 in 31.2%) controller drugs before the attack.
Conclusion: Providing country specific data on practice patterns in the management of acute
asthma attack in a representative cohort in Turkey, prescription of steroids and SABA
þ anticholinergics as the main drugs of choice was in line with guidelines while the significant rela-
tion of pre-attack asthma control to risk/severity of asthma attack and rate/duration of
hospitalization seem to be the leading results of the present study.
ª 2010 Elsevier Ltd. All rights reserved.itesi Tip Fakultesi, Gogus Hastaliklari Anabilim Dali, Ankara, Turkey. Tel.: þ90 312 2026112; fax: þ90
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Bronchial asthma is a common chronic disease in industri-
alized countries posing a significant burden on patients’
lives as well as on health economics.1,2 Having 300 million
sufferers worldwide with additional 100 million people
estimated to be affected by 2025,3 the number of patients
with asthma in Turkey has been estimated to be 3e4
million.4
While current asthma symptoms are known to have much
higher prevalence comparable with European countries,
the prevalence of physician diagnosed-asthma has been
reported to be approximately 3e5% among adult population
in Turkey,5e7 and 7% of asthma patients in Turkey have been
diagnosed with severe asthma.8
Failure in rational asthma treatment cause sub-optimal
control of symptoms and attack occurrence9 leading to
early and late unwanted consequences regarding social,
personal, and emotional lives of asthma patients in
a significant manner10 and increased burden of the disease
on the society and health system.11 Therefore, continuous
preventive management rather than symptom-driven and
crisis-oriented care has been recommended in several
national and international ‘asthma management’ guide-
lines12 in order to be able to reduce the overall burden of
poor control at all levels.11 Despite the presence of inter-
national and national asthma guidelines and effective
medications to achieve optimum control of the disease,5,13
published reports consistently revealed a low level of
disease control among asthma patients in many countries
including Turkey.14e16
Besides, it is obvious that rational approach to asthma
attack is crucial because of its life-threatening potential
and the associated economical burden. However, recent
attempts concerning development of standardized guide-
lines for asthma management have shown that unless
reflected in the daily practice, presence of appropriate
guidelines seems to lack clinical feedback.5 Therefore, the
present study was designed to evaluate patient character-
istics and practice patterns in the management of acute
asthma attack at tertiary care centers, retrospectively to
provide country specific data that will provide an insight to
the clinical practice in relation to attack severity in Turkey.
Methods
Study population
This national, multi-center study involving 294 patients with
persistent asthma admitted for healthcare service upon
symptoms of acute attack was conducted retrospectively at
15 different tertiary healthcare centers across Turkey. The
tertiary healthcare centers for chest diseases which were
selected by the Project Advisory Board of the study according
to the geographical distribution of specialists and family
physicians in Turkey as well as the distribution of investiga-
tors in relation to type of institutions they work (university
hospital, state hospital and chest diseases hospital) to be
representative of the country. In accordance with the real
life setting of the study based on routine clinical practice,
inclusion criteriawere kept to aminimum.Being18 years ofage, having diagnosis of persistent asthma and being
admitted to the hospital with symptoms of acute asthma
attack within the past 24 months were the inclusion criteria
of the study. Exclusion criteriawere composedof diagnosis of
asthma attack during patient’s routine visit and determina-
tion of less than 3 months interval between subsequent
admissions of the same patient related to acute asthma
attackwithin the screening period. The studywas conducted
in accordance with International Conference on Harmo-
nisation (ICH) e Good Clinical Practice (GCP) guideline and
local regulations.
Data were collected retrospectively from hospital
records belonging to the admissions to the emergency
departments or outpatient clinics of the selected medical
centers within the past 24 months due to an acute asthma
attack. Patients in the study population are amongst the
routine follow-up patients of the clinics participated in the
present study. Most of them were hospitalized patients
having detailed medical records of pre-attack asthma
control and severity. Patient demographics, asthma control
level, severity of the acute attack and the management of
the attack were the clinical parameters evaluated. Direct
costs for asthma attack management in these patients were
also calculated and the data are in preparation to be pre-
sented elsewhere.
Classification of asthma control level and the attack
severity
Asthma control level was classified as controlled, partly
controlled and uncontrolled based on daytime symptoms,
limitations of activities, nocturnal symptoms/awakening,
need for reliever/rescue treatment, lung function and the
number of exacerbations, while asthma attack severity was
categorized into four groups as mild, moderate, severe and
life-threatening based on Global Initiative for Asthma
(GINA) guidelines.5
Statistical analysis
Statistical analysis was made using computer software
(SPSS version 13.0, SPSS Inc. Chicago, IL, USA). Chi-square
(c2) test was used for the comparison of categorical data
and ManteleHaenszel test for the analysis of linear rela-
tionship between ordinal variables. ANOVA and post hoc
Tukey test were used for the parametric variables. Data
were expressed as “mean  standard deviation (SD)” and
percent (%) where appropriate. p < 0.05 was considered
statistically significant. Since life-threatening asthma
attacks were represented by only 4 cases, analysis for this
group was confined to descriptive statistics only. Therefore,
all of the comparisons considering severity of the attack
included mild, moderate and severe attacks.
Results
Demographic and clinical data
Eighty percent of the 294 patients included in our study
were females (n Z 236) and the overall mean age was
50.4  15.1 (range: 18e90) years (52.0  14.8 years for
1788 H. Tu¨rktas‚ et al.females and 43.7  14.4 years for males). First admission
was via the outpatient clinics by 68% of the patients
(nZ 200), while others (32%; nZ 94) have admitted to the
emergency departments. The majority of data were
obtained from the hospitalized patients (78.9%; n Z 232)
and there was no gender influence on the rate of hospi-
talization. Pre-attack asthma was determined to be partly
controlled in 46.9% of the patients, and the severity of the
attack was moderate in 57.5% (Table 1). There was no
significant difference in asthma control and attack severity
in terms of gender, but mean age was significantly higher in
patients with severe attacks (p < 0.01; Table 1). There was
a significant correlation between attack severity and pre-
attack asthma control (p < 0.001; Table 1).
Medications used in attack treatment and
diagnostic tests applied during the attack
Parenteral steroids in 72% of the patients and oral steroids
in 29% were the steroid drugs used in the treatment of
asthma attack. Bronchodilators that were used to treat the
attack were short-acting beta-agonists (SABA) in 53% and
ipratropium bromide þ salbutamol combination in 42% of
the patients (Table 2). Reflecting the way of bronchodilator
application, nebulizer was the most commonly used treat-
ment tool during acute attack (91.8%). Oxygen therapy was
used in 72.1% of the patients (Table 2). There was a signif-
icant increase in the use of parenteral steroids (p < 0.001),
theophylline (pZ 0.027), nebulizer (pZ 0.03) and oxygen
(p < 0.001) therapy by attack severity (Table 2).
Spirometry (85.4%), chest X-Ray (85.4%) and oxygen
saturation measurements (62.6%) were the most frequent
diagnostic tests used during the attack. When the relation
of attack severity to the diagnostic tests performed during
the asthma attack was considered, relationship betweenTable 1 Distribution of the patients and the relation between
Total, n (%)
Pre-attack asthma control
Controlled 41 (13.9)
Partly controlled 138 (46.9)
Uncontrolled 115 (39.1)
Attack severity
Mild 55 (18.7)
Moderate 169 (57.5)
Severe 66 (22.4)
Life-threatening 4 (1.4)
Attack severity n (%)
Mild Modera
Pre-attack asthma controlb
Controlled 17 (41.5) 22 (53
Partly controlled 32 (23.2) 90 (65
Uncontrolled 6 (5.2) 57 (49
Total 55 (18.7) 169 (57
*p < 0.05 compared to moderate attack.
a ManteleHaenszel test; c2: 3.95, p < 0.05; ANOVA.
b ManteleHaenszel test; c2: 55.1, p < 0.001 with respect to attackattack severity and the tests including peak expiratory flow
(PEF; p < 0.01), microbiological tests (p < 0.01), arterial
blood gas sampling (p < 0.001) and echocardiography
(p < 0.001) was determined to be significant (Table 3).
The relation between asthma control, attack
severity and hospitalizations
Among patients with controlled disease preceding the
attack, 56% were hospitalized while 78% of the patients
with partly controlled asthma and 88% of uncontrolled
asthma patients were hospitalized during the management
of the attack. The hospitalization rates according to attack
severity were as follows: 62% of mild, 78% of moderate, 94%
of severe and all life-threatening attacks. Inpatient follow-
up duration was significantly longer in uncontrolled asthma
(190.7  146.6 h) when compared to partly controlled
(141.0  139.7 h) and controlled (90.6  102.5 h) disease;
and in severe attack cases (228.7  150.8 h) compared to
moderate (141.0  132.9 h) and mild (85.8  95.8 h) attack
groups (p < 0.05). The degree of asthma control (p < 0.001)
and attack severity (p < 0.001) was significantly related to
hospitalization ratio, while outpatient follow-up duration
did not differ according to pre-attack asthma control and
attack severity.
Medications used before the asthma attack
Most of the patients were identified to be on combined
controller drug treatment (two controllers in 38.7% and 3e4
controllers in 31.2%) before the attack (Table 4). When
assessed according to the pre-attack asthma control and
attack severity, combined treatment with two controller
drugs was the most frequently used medications in patients
with controlled and partly controlled asthma as well as mildasthma control and asthma attack severity.
Females, n (%) Age, mean  SD
32 (13.6) 48.95  16.43
111 (47.0) 49.64  15.35
93 (39.4) 51.79  14.14
43 (18.2) 46.34  17.39a
139 (58.9) 49.19  18.26
53 (22.5) 54.41  30.93*
1 (0.4) 33.42  18.87
te Severe Life-threatening
.7) 2 (4.9%) 0 (0.0)
.2) 15 (10.9) 1 (0.7)
.6) 49 (42.6) 3 (2.6)
.5) 66 (22.4) 4 (1.4)
severity.
Table 2 Drug and non-drug treatment applied during the attack in relation to attack severity.
Attack severity
Totale n (%) Mild n (%) Moderate n (%) Severe n (%)
Drug treatment
Parenteral steroida 208 (71.7) 27 (49.1) 124 (73.4) 57 (86.4)
Oral steroid 83 (28.6) 14 (25.5) 48 (28.4) 21 (31.8)
Nebulized steroid 139 (47.9) 31 (56.4) 82 (48.5) 26 (39.4)
SABA 153 (52.8) 28 (50.9) 82 (48.5) 43 (65.2)
Theophyllineb 129 (44.5) 20 (36.4) 72 (42.6) 37 (56.1)
Anticholinergic 22 (7.6) 3 (5.5) 12 (7.1) 7 (10.6)
Magnesium 2 (0.7) 0 (0.0) 1 (0.6) 1 (1.5)
Ipratropium bromide þ salbutamol 120 (41.4) 21 (38.2) 67 (39.6) 43 (65.2)
Non-drug treatment
Nebulizerc 266 (91.7) 47 (85.5) 153 (90.5) 66 (100.0)
Oxygend 208 (71.7) 23 (41.8) 124 (73.4) 61 (92.4)
Non-invasive mechanical ventilation 3 (1.0) 0 (0.0) 1 (0.6) 2 (3.0)
SABA: short-acting beta2-agonist.
a ManteleHaenszel test; c2: 19.92, p < 0.001.
b ManteleHaenszel test; c2: 4.90, p Z 0.027.
c ManteleHaenszel test; c2: 8.64, p Z 0.03.
d ManteleHaenszel test; c2: 36.95, p < 0.001.
e Patients with life-threatening attack (n Z 4) were not included in this analysis.
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combined treatment with 3e4 controller drugs was the
most frequently selected treatment in patients with
uncontrolled asthma (38.2%). Overall, 90 patients (33.8%)
were using inhaled corticosteroid (ICS) þ LABA, and 82
patients (30.8%) were given extra controller drug(s) in
addition to ICS þ LABA. Medications used before asthma
attack were found to have a significant influence on pre-
attack asthma control (p < 0.001) but not on attack
severity (Table 4).Table 3 Relation between severity of acute attack and the tes
Tests performed during acute asthma attack Attack severity
Total n (%) Mil
PEF (via PEF-meter) 16 (5.5) 1
Spirometry (including FEV1) 247 (85.2) 46
Arterial blood gas sampling 161 (55.5) 19
Oxygen saturation 181 (62.4) 36
Chest XR 247 (85.2) 46
Electrocardiography 176 (60.7) 33
Microbiological tests 48 (16.6) 8
Complete blood count 107 (36.9) 19
Blood biochemistry 73 (25.2) 12
Thorax CT 9 (3.1) 3
Echocardiography 14 (4.8) 1
PEF: Peak expiratory flow; FEV1: forced expiratory volume in 1 s
a ManteleHaenszel test.
b c2 test.Discussion
According to our findings, as in line with the guidelines;
steroids and SABA þ anticholinergics were among the most
frequently prescribed agents in the treatment of acute
asthma attack in the study population while spirometry,
chest X-Ray and oxygen saturation were the most frequent
diagnostic tests performed during the attack. Additionally,
severity of asthma attack was significantly associated with
pre-attack control level of the disease.ts performed during attack.
c2 p
d n (%) Moderate n (%) Severe n (%)
(1.8) 6 (3.6) 9 (13.6) 8.6a 0.003
11.04b 0.004
(83.6) 147 (87.0) 54 (81.8) 0.12a 0.73
(34.5) 89 (52.7) 53 (80.3) 26.1a 0.000
26.7b 0.000
(65.5) 97 (57.4) 48 (72.7) 0.93a 0.94
(83.6) 148 (87.6) 53 (80.3) 0.37a 0.54
(60.0) 99 (58.6) 44 (66.7) 0.65a 0.42
(14.5) 20 (11.8) 20 (30.3) 6.2a 0.013
11.92b 0.003
(34.5) 68 (40.2) 20 (30.3) 0.33a 0.56
(21.8) 42 (24.9) 19 (28.8) 0.79a 0.38
(5.5) 3 (1.8) 3 (4.5) 0.03a 0.86
(1.8) 3 (1.8) 10 (15.2) 12.9a 0.000
19.8b 0.000
Table 4 Use of pre-attack medications in terms of pre-attack asthma control and attack severity.
Pre-attack medicationa Total n (%) Controlled n (%) Partly
controlled n (%)
Uncontrolled n (%)
Pre-attack asthma control
Symptom reliever only 39 (14.7) 8 (24.2) 16 (13.0) 15 (13.6)
Single controller drug 24 (9.0) 3 (9.1) 17 (13.8) 4 (3.6)
Combination of 2 controller drugs 103 (38.7) 14 (42.4) 53 (43.1) 36 (32.7)
Combination of 3 or 4 controller drugs 83 (31.2) 8 (24.2) 33 (26.8) 42 (38.2)
Systemic steroid þ any other medication 17 (6.4) 0 (0.0) 4 (3.3) 13 (11.8)
Total 266 (100.0) 33 (100.0) 123 (100.0) 110 (100.0)
Attack severityc
Pre-attack medicationb Total n (%) Mild n (%) Moderate n (%) Severe n (%)
Symptom reliever only 39 (14.7) 6 (12.5) 23 (15.1) 10 (16.1)
Single controller drug 24 (9.0) 4 (8.3) 18 (11.8) 1 (1.6)
Combination of 2 controller drugs 103 (38.7) 23 (47.9) 58 (38.2) 21 (33.9)
Combination of 3 or 4 controller drugs 83 (31.2) 13 (27.1) 47 (30.9) 22 (35.5)
Systemic steroid þ any other medication 17 (6.4) 2 (4.2) 6 (3.9) 8 (12.9)
Totalc 266 (100.0) 48 (100.0) 152 (100.0) 62 (100.0)
a ManteleHaenszel test; c2: 10.99, p Z 0.001.
b ManteleHaenszel test; c2: 1.72; p Z 0.19.
c Patients admitted with life-threatening asthma attacks (n Z 4) were administered anti-inflammatory monotherapy (25%), combi-
nation of two controllers (25%), combination of 3 or 4 controllers (25%) or systemic steroid þ any controller (25%).
1790 H. Tu¨rktas‚ et al.Steroids were administered via parenteral route in 72%
of our patients despite no documented superiority to oral
steroids. This may be assumed to be associated with the
availability of intravenous therapy line among hospitalized
patients.
Although the benefit as add-on treatment in adults with
severe asthma exacerbations has not been demonstrated,
use of theophylline in an amount (44.9%) exceeding the
number of our patients with severe attack is another finding
of this study to be considered. Besides magnesium was used
very rarely in our patients despite recommendations con-
cerning magnesium use prior to theophylline in interna-
tional guidelines.5
Pronounced preference of nebulizer rather than spacer
by our physicians despite similar efficacy shown for both in
the management of acute asthma attack may be related to
higher availability of SABA and anticholinergic combinations
in nebulized forms under hospital conditions.
Use of nebulized steroids as a drug of choice in almost
half of the study population indicates deviation from the
guidelines in the real life practice in the management of
acute asthma. However, use of inhaled corticosteroids in
the management of asthma exacerbations in the secondary
care was reported to range from 34% to 75% in an interna-
tional observational prospective study to determine the
cost of asthma exacerbations (COAX).9
Represented by rather high rates (85%) than the actual
need in asthma attack assessment, chest X-Ray seems to be
ordered as a part of the routine hospitalization procedures.
Likewise, frequent use of microbiological tests, arterial
blood gas sampling and echocardiography in severe attack
may be explained by expected co-morbidities and need to
monitor arterial blood gas values in severe attacks.
Spirometry rates in our population (85%) were in line with
the rates documented for management of acute asthmaattack in the secondary care (ranged 40e100%) in COAX
study.9
One of the striking findings of the present study is the
high hospitalization rate determined in admissions with
acute asthma attack. Indeed, hospitalization rate reaching
62% of the patients with mild attack may be associated with
the characteristics of Turkish healthcare system allowing
admission of patients directly to the tertiary centers which
was the sole hospital type included according to the study
protocol. In this respect, the decision of hospitalization
aiming short-term follow-up may be based on certain socio-
economic circumstances such as the distance from the
territory that the patient originally lives. In fact, to be able
to encourage patient education and to enable future
success of the disease management, physicians may prefer
hospitalization regardless of the attack severity, especially
for the patients considered to have higher likelihood of
incompliance in our country.
While the primary objective of the present study was
to evaluate practice patterns in the management of
acute asthma attack, our results seem to indicate that
the pre-attack control level of the asthma disease was
significantly associated with attack development and
hospitalization. Accordingly, our data on the significant
relation between low level of disease control and risk of
attack development, attack severity as well as high
incidence and longer duration of hospitalization are in
line with the recently documented association between
uncontrolled asthma and future asthma-related events
including the course of oral steroids, emergency room
visit, and hospitalization.17
Consistent with remarkable alteration in practice
patterns in the asthma management in the last decade, an
increase in the prescription rate of controller medications
including multiple controllers as shown in our study for
Appendix A
ADVISE study group (by the site’s number)
01. Yedikule Chest Diseases and Chest Surgery Training and
Research Hospital, Istanbul e Principal Investigator
(PI): Sedat Altın, MD.
02. Istanbul University, Cerrahpasa Faculty of Medicine,
Istanbul e PI: Bilun Gemicioglu, MD, PhD.
03. Dr. Lu¨tfi Kırdar Kartal Training and Research Hospital,
Istanbul e PI: Benan Caglayan, MD.
04. Dr. Suat Seren Chest Diseases and Thoracic Surgery
Training and Research Hospital, Izmir e PI: Ali Kadri
Cirak, MD.
05. Ege University Faculty of Medicine, Izmir e PI: Mu¨nev-
ver Erdinc, MD.
06. Ataturk Chest Diseases Training and Research Hospital,
Ankara e PI: Serdar Akpinar, MD.
07. Ankara University Faculty of Medicine Cebeci Hospital,
Ankara e PI: Omur Aydin, MD.
08. Gazi University Faculty of Medicine, Ankara e PI: Haluk
Turktas, MD.
09. Dıs‚kapı Yıldırım Beyazıt Training and Research Hospital,
Ankara e PI: Sadik Ardic¸, MD.
10. Trabzon Chest Diseases Hospital, Trabzon e PI: Yilmaz
Bektas, MD.
11. Karadeniz Technical University Faculty of Medicine,
Trabzon e PI: Tevfik Ozlu, MD.
12. Prof. Dr. Nusret Karasu Chest Diseases Hospital, Adana
e PI: Nezaket Erdogan, MD.
13. Mersin University Faculty of Medicine, Mersin e PI:
Sibel Atis, MD.
14. Inonu University Turgut Ozal Medical Center, Malatya e
PI: Hakan Gunen, MD.
15. Dicle University Faculty of Medicine, Diyarbakir e PI:
Fusun Topcu, MD.
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since Asthma Insights and Reality (AIR) surveys by which low
level of asthma control set by the guidelines in the US,
Europe, Asia-Pacific, Japan and Latin America populations
was reported.18e22 Likewise, in a past study concerning
determinants of asthma control at tertiary healthcare level
in Turkey, use of ICS and LABA combination was identified in
57% of overall 900 patients included in the study.16 As a
matter of fact, despite widespread use of pre-attack
asthma controllers in our population, the percentage of
patients identified with uncontrolled asthma reach almost
40%. This finding is in line with the necessity of improve-
ment in certain issues beyond prescribing asthma medica-
tions such as patient education about different facets of
asthma control and treatment adherence as documented in
the recent survey on determinants of asthma control at
tertiary healthcare level in Turkey.16
The major limitation of the present study was the
retrospective design increasing the possibility of missing
data due to deficits in the records available in the patients’
files. While seems reasonable in relation to the nature of
the study that aims to evaluate the real life practice in the
asthma management, the liberal exclusion/inclusion
criteria defined in the study protocol is another potential
criticism of the methodological approach. Likewise, as
another limitation of the study, based on predominance of
data selected from hospitalized patients in the whole
population, there is at least theoretical possibility of
selection bias in the patients recruited to the study.
Nevertheless, since hospital records were kept better for
hospitalized patients, this kind of selection was necessary
to guarantee the quality of data with respect to criteria
defined in the protocol. Finally, albeit data on potential
differences between different regions in terms of practices
to handle asthma attacks is expected to be reported in
a nation-wide report, the number of subjects included from
each center in the present study did not allow assessment
of such inhomogeneities.
In conclusion, providing country specific data on patient
characteristics and practice patterns in the management of
acute asthma attack at tertiary healthcare centers in
a cohort representative of geographical distribution of the
physicians who are managing asthma in Turkey, prescription
of steroids and SABA þ anticholinergics as the main drugs of
choice was in line with guidelines. The significant relation of
pre-attack asthma control to risk/severity of asthma attack
and rate/duration of hospitalization seem to be among the
leading results of the present study. Besides enabling
a baseline scale for future national studies on practice
pattern in asthmamanagement, our data further support the
necessity of prompt adoption to therapeutic and preventive
measures indicated in the guidelines by the physicians for
better and stricter asthma control achievement and to
prevent unnecessary hospitalization of asthma patients.Acknowledgment
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